Cargando…

A safe and effective treatment combination of neoadjuvant therapy and surgical resection for metastatic TFE3-rearranged renal cell carcinoma:a case report

TFE3-rearranged renal cell carcinoma (RCC) is a rare subtype of renal tumor that primarily affects young women and is characterized by early metastasis and a poor prognosis. This case study presents a 29-year-old woman diagnosed with TFE3-rearranged RCC, who initially presented with painless gross h...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Haiyang, Dong, Xiang, Pan, Xinghe, Ma, Wenliang, Pan, Jun, Guo, Hongqian, Gan, Weidong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10627181/
https://www.ncbi.nlm.nih.gov/pubmed/37936602
http://dx.doi.org/10.3389/fonc.2023.1252282
_version_ 1785131486806016000
author Yang, Haiyang
Dong, Xiang
Pan, Xinghe
Ma, Wenliang
Pan, Jun
Guo, Hongqian
Gan, Weidong
author_facet Yang, Haiyang
Dong, Xiang
Pan, Xinghe
Ma, Wenliang
Pan, Jun
Guo, Hongqian
Gan, Weidong
author_sort Yang, Haiyang
collection PubMed
description TFE3-rearranged renal cell carcinoma (RCC) is a rare subtype of renal tumor that primarily affects young women and is characterized by early metastasis and a poor prognosis. This case study presents a 29-year-old woman diagnosed with TFE3-rearranged RCC, who initially presented with painless gross hematuria. Computed Tomography (CT) imaging revealed the presence of a solid mass in the left kidney along with retroperitoneal metastasis. The patient received axitinib, a vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFR-TKI), as first-line neoadjuvant therapy. Subsequent testing confirmed positive expression of programmed death-1 protein L1 (PDL1), leading to the addition of tislelizumab, a PD1 inhibitor, to the treatment regimen. After 8 months, the patient’s tumor size and metastases exhibited significant reduction, providing a favorable opportunity for subsequent surgical intervention. The tumor was classified as IV (pT3aN0M1) based on the pathologic stage of the American Joint Committee on Cancer (AJCC, 8th edition, 2017). The patient achieved long-term survival through combined systemic therapy involving surgery and neoadjuvant treatment. At the 30-month follow-up, there was no evidence of tumor recurrence or metastasis.
format Online
Article
Text
id pubmed-10627181
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-106271812023-11-07 A safe and effective treatment combination of neoadjuvant therapy and surgical resection for metastatic TFE3-rearranged renal cell carcinoma:a case report Yang, Haiyang Dong, Xiang Pan, Xinghe Ma, Wenliang Pan, Jun Guo, Hongqian Gan, Weidong Front Oncol Oncology TFE3-rearranged renal cell carcinoma (RCC) is a rare subtype of renal tumor that primarily affects young women and is characterized by early metastasis and a poor prognosis. This case study presents a 29-year-old woman diagnosed with TFE3-rearranged RCC, who initially presented with painless gross hematuria. Computed Tomography (CT) imaging revealed the presence of a solid mass in the left kidney along with retroperitoneal metastasis. The patient received axitinib, a vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFR-TKI), as first-line neoadjuvant therapy. Subsequent testing confirmed positive expression of programmed death-1 protein L1 (PDL1), leading to the addition of tislelizumab, a PD1 inhibitor, to the treatment regimen. After 8 months, the patient’s tumor size and metastases exhibited significant reduction, providing a favorable opportunity for subsequent surgical intervention. The tumor was classified as IV (pT3aN0M1) based on the pathologic stage of the American Joint Committee on Cancer (AJCC, 8th edition, 2017). The patient achieved long-term survival through combined systemic therapy involving surgery and neoadjuvant treatment. At the 30-month follow-up, there was no evidence of tumor recurrence or metastasis. Frontiers Media S.A. 2023-10-23 /pmc/articles/PMC10627181/ /pubmed/37936602 http://dx.doi.org/10.3389/fonc.2023.1252282 Text en Copyright © 2023 Yang, Dong, Pan, Ma, Pan, Guo and Gan https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Yang, Haiyang
Dong, Xiang
Pan, Xinghe
Ma, Wenliang
Pan, Jun
Guo, Hongqian
Gan, Weidong
A safe and effective treatment combination of neoadjuvant therapy and surgical resection for metastatic TFE3-rearranged renal cell carcinoma:a case report
title A safe and effective treatment combination of neoadjuvant therapy and surgical resection for metastatic TFE3-rearranged renal cell carcinoma:a case report
title_full A safe and effective treatment combination of neoadjuvant therapy and surgical resection for metastatic TFE3-rearranged renal cell carcinoma:a case report
title_fullStr A safe and effective treatment combination of neoadjuvant therapy and surgical resection for metastatic TFE3-rearranged renal cell carcinoma:a case report
title_full_unstemmed A safe and effective treatment combination of neoadjuvant therapy and surgical resection for metastatic TFE3-rearranged renal cell carcinoma:a case report
title_short A safe and effective treatment combination of neoadjuvant therapy and surgical resection for metastatic TFE3-rearranged renal cell carcinoma:a case report
title_sort safe and effective treatment combination of neoadjuvant therapy and surgical resection for metastatic tfe3-rearranged renal cell carcinoma:a case report
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10627181/
https://www.ncbi.nlm.nih.gov/pubmed/37936602
http://dx.doi.org/10.3389/fonc.2023.1252282
work_keys_str_mv AT yanghaiyang asafeandeffectivetreatmentcombinationofneoadjuvanttherapyandsurgicalresectionformetastatictfe3rearrangedrenalcellcarcinomaacasereport
AT dongxiang asafeandeffectivetreatmentcombinationofneoadjuvanttherapyandsurgicalresectionformetastatictfe3rearrangedrenalcellcarcinomaacasereport
AT panxinghe asafeandeffectivetreatmentcombinationofneoadjuvanttherapyandsurgicalresectionformetastatictfe3rearrangedrenalcellcarcinomaacasereport
AT mawenliang asafeandeffectivetreatmentcombinationofneoadjuvanttherapyandsurgicalresectionformetastatictfe3rearrangedrenalcellcarcinomaacasereport
AT panjun asafeandeffectivetreatmentcombinationofneoadjuvanttherapyandsurgicalresectionformetastatictfe3rearrangedrenalcellcarcinomaacasereport
AT guohongqian asafeandeffectivetreatmentcombinationofneoadjuvanttherapyandsurgicalresectionformetastatictfe3rearrangedrenalcellcarcinomaacasereport
AT ganweidong asafeandeffectivetreatmentcombinationofneoadjuvanttherapyandsurgicalresectionformetastatictfe3rearrangedrenalcellcarcinomaacasereport
AT yanghaiyang safeandeffectivetreatmentcombinationofneoadjuvanttherapyandsurgicalresectionformetastatictfe3rearrangedrenalcellcarcinomaacasereport
AT dongxiang safeandeffectivetreatmentcombinationofneoadjuvanttherapyandsurgicalresectionformetastatictfe3rearrangedrenalcellcarcinomaacasereport
AT panxinghe safeandeffectivetreatmentcombinationofneoadjuvanttherapyandsurgicalresectionformetastatictfe3rearrangedrenalcellcarcinomaacasereport
AT mawenliang safeandeffectivetreatmentcombinationofneoadjuvanttherapyandsurgicalresectionformetastatictfe3rearrangedrenalcellcarcinomaacasereport
AT panjun safeandeffectivetreatmentcombinationofneoadjuvanttherapyandsurgicalresectionformetastatictfe3rearrangedrenalcellcarcinomaacasereport
AT guohongqian safeandeffectivetreatmentcombinationofneoadjuvanttherapyandsurgicalresectionformetastatictfe3rearrangedrenalcellcarcinomaacasereport
AT ganweidong safeandeffectivetreatmentcombinationofneoadjuvanttherapyandsurgicalresectionformetastatictfe3rearrangedrenalcellcarcinomaacasereport